Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial

Marshall Elam, Donald B. Hunninghake, Kathryn B. Davis, Rekha Garg, Craig Johnson, Debra Egan, John B. Kostis, David S. Sheps, Eliot A. Brinton

Research output: Contribution to journalArticle

451 Citations (Scopus)

Abstract

Context: Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data. Objective: To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes. Design and Setting: Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995. Participants: A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease. Interventions: After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind). Main Outcome Measures: Plasma lipoprotein, glucose, hemoglobin A(1c) (HbA(1c)), alanine aminotransferase, and uric acid levels; hypoglycemic drug use; compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo. Results: Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and low-density lipoprotein cholesterol (LDL-C) by 8% and 9%, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0% and 2% in HDL-C and increases of 7% and 0% in triglycerides, and increases of 1% and 1% in LDL-C. Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P=.04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA(1c) were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA(1c) decreased by 0.3% (P=.04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. Conclusions: Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels.

Original languageEnglish (US)
Pages (from-to)1263-1270
Number of pages8
JournalJournal of the American Medical Association
Volume284
Issue number10
DOIs
StatePublished - Sep 13 2000

Fingerprint

Niacin
Peripheral Arterial Disease
Lipoproteins
Lipids
Placebos
Hemoglobin A
HDL Cholesterol
Hypoglycemic Agents
LDL Cholesterol
Triglycerides
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Glucose
Hypertriglyceridemia
Uric Acid
Alanine Transaminase
LDL Lipoproteins
Compliance

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease : The ADMIT study: A randomized trial. / Elam, Marshall; Hunninghake, Donald B.; Davis, Kathryn B.; Garg, Rekha; Johnson, Craig; Egan, Debra; Kostis, John B.; Sheps, David S.; Brinton, Eliot A.

In: Journal of the American Medical Association, Vol. 284, No. 10, 13.09.2000, p. 1263-1270.

Research output: Contribution to journalArticle

Elam, Marshall ; Hunninghake, Donald B. ; Davis, Kathryn B. ; Garg, Rekha ; Johnson, Craig ; Egan, Debra ; Kostis, John B. ; Sheps, David S. ; Brinton, Eliot A. / Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease : The ADMIT study: A randomized trial. In: Journal of the American Medical Association. 2000 ; Vol. 284, No. 10. pp. 1263-1270.
@article{d4aa1289c4e54a599a23d080035fba14,
title = "Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial",
abstract = "Context: Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data. Objective: To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes. Design and Setting: Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995. Participants: A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease. Interventions: After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind). Main Outcome Measures: Plasma lipoprotein, glucose, hemoglobin A(1c) (HbA(1c)), alanine aminotransferase, and uric acid levels; hypoglycemic drug use; compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo. Results: Niacin use significantly increased HDL-C by 29{\%} and 29{\%} and decreased triglycerides by 23{\%} and 28{\%} and low-density lipoprotein cholesterol (LDL-C) by 8{\%} and 9{\%}, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0{\%} and 2{\%} in HDL-C and increases of 7{\%} and 0{\%} in triglycerides, and increases of 1{\%} and 1{\%} in LDL-C. Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P=.04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA(1c) were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA(1c) decreased by 0.3{\%} (P=.04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. Conclusions: Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels.",
author = "Marshall Elam and Hunninghake, {Donald B.} and Davis, {Kathryn B.} and Rekha Garg and Craig Johnson and Debra Egan and Kostis, {John B.} and Sheps, {David S.} and Brinton, {Eliot A.}",
year = "2000",
month = "9",
day = "13",
doi = "10.1001/jama.284.10.1263",
language = "English (US)",
volume = "284",
pages = "1263--1270",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease

T2 - The ADMIT study: A randomized trial

AU - Elam, Marshall

AU - Hunninghake, Donald B.

AU - Davis, Kathryn B.

AU - Garg, Rekha

AU - Johnson, Craig

AU - Egan, Debra

AU - Kostis, John B.

AU - Sheps, David S.

AU - Brinton, Eliot A.

PY - 2000/9/13

Y1 - 2000/9/13

N2 - Context: Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data. Objective: To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes. Design and Setting: Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995. Participants: A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease. Interventions: After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind). Main Outcome Measures: Plasma lipoprotein, glucose, hemoglobin A(1c) (HbA(1c)), alanine aminotransferase, and uric acid levels; hypoglycemic drug use; compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo. Results: Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and low-density lipoprotein cholesterol (LDL-C) by 8% and 9%, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0% and 2% in HDL-C and increases of 7% and 0% in triglycerides, and increases of 1% and 1% in LDL-C. Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P=.04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA(1c) were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA(1c) decreased by 0.3% (P=.04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. Conclusions: Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels.

AB - Context: Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data. Objective: To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes. Design and Setting: Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995. Participants: A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease. Interventions: After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind). Main Outcome Measures: Plasma lipoprotein, glucose, hemoglobin A(1c) (HbA(1c)), alanine aminotransferase, and uric acid levels; hypoglycemic drug use; compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo. Results: Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and low-density lipoprotein cholesterol (LDL-C) by 8% and 9%, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0% and 2% in HDL-C and increases of 7% and 0% in triglycerides, and increases of 1% and 1% in LDL-C. Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P=.04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA(1c) were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA(1c) decreased by 0.3% (P=.04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. Conclusions: Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels.

UR - http://www.scopus.com/inward/record.url?scp=0034644442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034644442&partnerID=8YFLogxK

U2 - 10.1001/jama.284.10.1263

DO - 10.1001/jama.284.10.1263

M3 - Article

C2 - 10979113

AN - SCOPUS:0034644442

VL - 284

SP - 1263

EP - 1270

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 10

ER -